Par-SN: A Potential Drug Target and Biomarker for the Treatment of Paroxysmal Non-Epileptic Sleep Disorders

Target Name: PWARSN

NCBI ID: G347746

PWARSN

Other Name(s): PAR-SN | PARSN | Prader Willi/Angelman region RNA, SNRPN neighbor

Par-SN: A Potential Drug Target and Biomarker for the Treatment of Paroxysmal Non-Epileptic Sleep Disorders

Abstract:

Paroxysmal non-epileptic sleep disorders (PNES) are a common sleep disorder that affects millions of people worldwide, characterized by recurring episodes of insomnia, rapid eye movement (REM) sleep, and vivid dreams. Despite the significant impact of PNES on quality of life , there are currently no approved disease-modifying treatments available. ThePar-SN gene, located on chromosome 11p15, has been identified as a potential drug target and biomarker for the treatment of PNES. This article summarizes the current understanding of Par-SN, its potential role as a drug target, and its potential as a biomarker for the diagnosis and progression of PNES.

Introduction:

Paroxysmal non-epileptic sleep disorders (PNES) are a common sleep disorder that affects millions of people worldwide, with estimates suggesting that up to 20% of the population experiences insomnia at least once a week. PNES is characterized by recurrent episodes of insomnia, rapid eye movement (REM) sleep, and vivid dreams. Despite the significant impact of PNES on quality of life, there are currently no approved disease-modifying treatments available.

ThePar-SN gene:

ThePar-SN gene, located on chromosome 11p15, is a potential drug target and biomarker for the treatment of PNES. ThePar-SN gene encodes a protein known as Par-SN, which is involved in the regulation of sleep-wake cycles and REM sleep. Par-SN is a non-coding RNA molecule that has been shown to play a role in the regulation of sleep-wake cycles and REM sleep.

The potential drug target:

ThePar-SN gene has been shown to be involved in the regulation of sleep-wake cycles andREM sleep, making it a potential drug target for the treatment of PNES. Activating Par-SN has been shown to increase rapid eye movement (REM) sleep and decrease insomnia symptoms in animal models of PNES.

The potential biomarker:

ThePar-SN gene has also been shown to be involved in the regulation of gene expression, which makes it a potential biomarker for the diagnosis and progression of PNES. By analyzing the expression of Par-SN, researchers have been able to identify potential biomarkers for the diagnosis and progression of PNES, such as increased Par-SN expression in individuals with PNES compared to healthy individuals.

Current research:

While further research is needed, studies have shown that thePar-SN gene is a promising drug target and biomarker for the treatment of PNES. Activating Par-SN has been shown to increase rapid eye movement (REM) sleep and decrease insomnia symptoms in animal models of PNES. Further studies are needed to determine the effectiveness ofPar-SN as a drug treatment for PNES and to identify potential biomarkers for the diagnosis and progression of PNES.

Conclusion:

Paroxysmal non-epileptic sleep disorders (PNES) are a common sleep disorder that affects millions of people worldwide, characterized by recurrent episodes of insomnia, rapid eye movement (REM) sleep, and vivid dreams. Despite the significant impact of PNES on quality of life , there are currently no approved disease-modifying treatments available. ThePar-SN gene, located on chromosome 11p15, has been identified as a potential drug target and biomarker for the treatment of PNES. Further research is needed to determine the effectiveness ofPar-SN as a drug treatment for PNES and to identify potential biomarkers for the diagnosis and progression of PNES.

Protein Name: Prader Willi/Angelman Region RNA, SNRPN Neighbor

The "PWARSN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PWARSN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets